Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

  • Technology appraisal guidance
  • TA218
  • Published: 

TA218 - Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia - Appendix B - proposal paper presented to the Institute's Guidance Executive

This page was last updated: 17 February 2014